Imasawa Toshiyuki, Hirano Daishi, Nozu Kandai, Kitamura Hiroshi, Hattori Motoshi, Sugiyama Hitoshi, Sato Hiroshi, Murayama Kei
Department of Nephrology, National Hospital Organization Chiba-Higashi National Hospital, Chiba, Japan.
Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
Kidney Int Rep. 2022 Jan 11;7(3):580-590. doi: 10.1016/j.ekir.2021.12.028. eCollection 2022 Mar.
The clinicopathologic characteristics of nephropathy associated with mitochondrial disease (MD) remain unknown. We retrospectively analyzed a cohort of patients with proteinuria, decreased glomerular filtration rate, or Fanconi syndrome who had a genetic mutation confirmed as the cause of MD, defined as mitochondrial nephropathy.
This nationwide survey included 757 nephrology sections throughout Japan, and consequently, data on 81 cases of mitochondrial nephropathy were collected.
The most common renal manifestation observed during the disease course was proteinuria. Hearing loss was the most common comorbidity; a renal-limited phenotype was observed only in mitochondrial DNA (mtDNA) point mutation and COQ8B mutation cases. We found a median time delay of 6.0 years from onset of renal manifestations to diagnosis. Focal segmental glomerular sclerosis (FSGS) was the most common pathologic diagnosis. We then focused on 63 cases with the m.3243A>G mutation. The rate of cases with diabetes was significantly higher among adult-onset cases than among childhood-onset cases. Pathologic diagnoses were more variable in adult-onset cases, including diabetic nephropathy, nephrosclerosis, tubulointerstitial nephropathy, and minor glomerular abnormalities. During the median observation period of 11.0 years from the first onset of renal manifestations in patients with m.3243A>G, renal replacement therapy (RRT) was initiated in 50.8% of patients. Death occurred in 25.4% of the patients during the median observation period of 12.0 years. The median estimated glomerular filtration rate (eGFR) decline was 5.4 ml/min per 1.73 m/yr in the cases, especially 8.3 ml/min per 1.73 m/yr in FSGS cases, with m.3243A>G.
Here, we described the clinicopathologic features and prognosis of mitochondrial nephropathy using large-scale data.
与线粒体疾病(MD)相关的肾病的临床病理特征尚不清楚。我们回顾性分析了一组蛋白尿、肾小球滤过率降低或范科尼综合征患者,这些患者的基因突变被确认为MD的病因,定义为线粒体肾病。
这项全国性调查涵盖了日本各地的757个肾内科科室,最终收集了81例线粒体肾病的数据。
疾病过程中观察到的最常见肾脏表现是蛋白尿。听力丧失是最常见的合并症;仅在线粒体DNA(mtDNA)点突变和COQ8B突变病例中观察到肾脏局限性表型。我们发现从肾脏表现出现到诊断的中位时间延迟为6.0年。局灶节段性肾小球硬化(FSGS)是最常见的病理诊断。然后我们重点关注了63例m.3243A>G突变的病例。成人发病病例中糖尿病的发生率显著高于儿童发病病例。成人发病病例的病理诊断更多样化,包括糖尿病肾病、肾硬化、肾小管间质性肾病和轻微肾小球异常。在m.3243A>G患者首次出现肾脏表现后的中位观察期11.0年期间,50.8%的患者开始接受肾脏替代治疗(RRT)。在中位观察期12.0年期间,25.4%的患者死亡。这些病例的中位估计肾小球滤过率(eGFR)下降为每年每1.73平方米5.4毫升/分钟,特别是FSGS病例中m.3243A>G的患者为每年每1.73平方米8.3毫升/分钟。
在此,我们使用大规模数据描述了线粒体肾病的临床病理特征和预后。